Laparoscopic Gastrectomy May Be Preferable After Gastric-Cancer Chemo Laparoscopic Gastrectomy May Be Preferable After Gastric-Cancer Chemo
In patients with locally advanced gastric cancer, laparoscopy-assisted distal gastrectomy (LADG) after neoadjuvant chemotherapy appears to offer more short-term benefits than does open gastrectomy, according to Chinese researchers.Reuters Health Information
Conditions: Gastric Cancer; Chemotherapy Effect Interventions: Drug: Chemotherapy drug; Procedure: Gastrectomy; Procedure: Laparoscopic exploration Sponsor: Chinese PLA General Hospital Not yet recruiting
Authors: Chia DKA, So JBY Abstract Peritoneal metastasis (PM) frequently occurs in patients with gastric cancer (GC) and confers a dismal prognosis despite advances in systemic chemotherapy. While systemic chemotherapy has poor peritoneal penetration, intraperitoneal (IP) chemotherapy remains sequestered, resulting in high peritoneal drug concentrations with less systemic side-effects. The first application of IP treatment was hyperthermic intraperitoneal chemotherapy (HIPEC) with cytoreductive surgery (CRS) for gastric cancer peritoneal metastasis (GCPM); but was associated with an increased morbidity and mortalit...
Conclusions: These findings suggest that FLOT neoadjuvant chemotherapy, followed by laparoscopic D2 gastrectomy, is effective and safe in advanced, resectable advanced gastric cancer. PMID: 32566545 [PubMed - in process]
Even though treatment modalities such as adjuvant systemic radio-chemotherapy and neoadjuvant chemotherapy (NAC) have individually have improved overall survival (OS) and progression-free survival (PFS) rates ...
In Reply We appreciate the thoughtful responses from Rosa and Alfieri to our article on the safety of laparoscopic gastrectomy after neoadjuvant chemotherapy in a pilot randomized clinical trial (RCT). Preoperative chemotherapy and laparoscopic surgery for advanced gastric cancer have been a research hotspot for nearly 20 years. However, high-quality evidence on efficacy and safety of laparoscopic gastrectomy in patients with neoadjuvant chemotherapy is absent, which drove us to conduct this single-center pilot RCT. We estimated the sample size based on primary outcome (3-year recurrence free survival) and recruited the re...
To the Editor We read with great interest the article by Li et al who compared, in a phase 2, open-label, noninferiority randomized clinical trial, laparoscopic distal gastrectomy and open distal gastrectomy in patients with clinical T2-T4N+M0 gastric cancer (GC) who were receiving neoadjuvant chemotherapy.
Conclusions: The selections and short-term surgical outcomes of LG for GC were widely different between East and West. To obtain more objective and accurate results, these differences should be considered in future international prospective studies.
Laparoscopy-assisted distal gastrectomy offered better short-term, post-surgical outcomes for patients with locally advanced gastric cancer who were undergoing neoadjuvant chemotherapy.